<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855062</url>
  </required_header>
  <id_info>
    <org_study_id>Uganda minocycline study</org_study_id>
    <secondary_id>Grant Number: 5 UO1 NS32228</secondary_id>
    <nct_id>NCT00855062</nct_id>
  </id_info>
  <brief_title>Minocycline for HIV+ Cognitive Impairment in Uganda</brief_title>
  <official_title>Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline,
      an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive
      impairment in Uganda.

      Study Design: Treatment, 24-week Randomized, Placebo-Controlled, Double-Blind Phase with
      Optional 24-week Open Label Phase for Subjects with a cluster of differentiation 4 (CD4)
      Count in the 251-350 Range

        -  Arm 1: Minocycline 100 mg orally every 12 hours (50 subjects)

        -  Arm 2: Matching placebo orally every 12 hours (50 subjects)

      Primary Objective:

      · To examine whether minocycline treatment will improve cognitive performance after 24 weeks
      compared to baseline

      Secondary Objectives:

        -  To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in
           individuals with HIV-associated cognitive impairment

        -  To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in
           individuals with HIV-associated cognitive impairment

        -  To examine whether minocycline treatment for 24 weeks improves functional impairment
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended
    to terminate the study early due to futility on 11/6/2009.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The U NP Sum is defined as the average of z scores for 9 neuropsychological test subcomponents in the neuropsychological test battery (i.e. the average of norm-adjusted (&quot;z&quot;) scores for Grooved Pegboard Dominant Hand, Grooved Pegboard Non-dominant Hand, Color Trails 1, Color Trails 2, Symbol Digit, WHO-UCLA Verbal Learning test Trial 5, WHO-UCLA Verbal Learning test delayed recall, Digit Span forward and Digit Span backward). The outcome is defined as U NP Sum at week 24 - U NP Sum at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Change of Karnofsky Performance Score</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.</measure>
    <time_frame>Time of initial Grade ≥ 2 toxicity and/or sign and symptom event up to week 24</time_frame>
    <description>The outcome is the time to first Grade ≥ 2 toxicity and/or sign and symptoms from study treatment initiation up to week 24. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms</measure>
    <time_frame>Time of first Grade ≥ 2 toxicity and/or sign and symptom event up to 48 weeks</time_frame>
    <description>The outcome is the time of first Grade ≥ 2 toxicity and/or sign and symptoms from treatment initiation up to 48 weeks. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Change of CD4 Cell Counts</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is defined as CD4 cell count at week 24 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>48-week Change of CD4 Cell Counts</measure>
    <time_frame>At baseline and week 48</time_frame>
    <description>The outcome is defined as CD4 cell count at week 48 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Change of Instrumental Activities of Daily Living</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is the HIV RNA plasma viral loads (Log10 transformed) at week 24 - the viral loads (Log10 transformed) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score</measure>
    <time_frame>At baseline and week 24</time_frame>
    <description>The outcome is the total CES-D score at week 24 - the total CES-D score at baseline.
The total CES-D score is based on 20 CES-D items, such as &quot;I was bothered by things that usually don't bother me&quot; and &quot;I did not feel like eating, my appetite was poor&quot;. Patients were asked to answer each item by 4 scales: (1) Rarely, (2) Sometimes, (3) Occasionally, and (4) Most of the time. After 4 negative items were multiplied by -1, the total CES-D score is a simple sum of all items.
The min and Max are 0 and 60, respectively. Higher scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>HIV-associated Cognitive Impairment</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline 100 mg orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo minocycline capsules every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>minocycline</intervention_name>
    <description>100 mg capsule every 12 hours by mouth</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>minocycline placebo capsule</intervention_name>
    <description>1 capsule every 12 hours by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection prior to study entry

          -  Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy
             by cluster of differentiation 4 (CD4) criteria in Uganda

          -  Negative serum or urine pregnancy test for women of childbearing potential

          -  Willingness to use birth control

          -  Age 18-65 years

          -  AIDS Dementia Scale Stage 0.5 OR 1

          -  Impaired cognitive performance as evidenced by an International HIV Dementia Scale
             (HDS) as defined by the protocol

          -  Ability to sit or stand and swallow intact capsules with an 8-ounce glass of water

          -  Ability and willingness of subject or legal guardian/ representative to give written
             informed consent

          -  Resident within a 20km radius of Kampala city

        Exclusion Criteria:

          -  Current cancers other than basal cell carcinoma, in situ carcinoma of the cervix, or
             Kaposi's sarcoma without evidence of visceral involvement or which does not require
             systemic chemotherapy

          -  Severe premorbid psychiatric illness, including schizophrenia and major depression
             which, in the in investigator's opinion, is likely to interfere with study compliance

          -  Active symptomatic AIDS-defining opportunistic infection within 45 days prior to study
             entry

          -  Confounding neurological disorders as defined in the protocol

          -  Central nervous system infections or cancers as defined in the protocol

          -  Systemic lupus

          -  Thyroid disease diagnosed within 24 weeks prior to entry

          -  Breastfeeding

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements

          -  Serious illness requiring systemic treatment and/or hospitalization until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigator

          -  History of allergy/sensitivity to minocycline or other tetracyclines and their
             formulations

          -  Any other clinically significant condition or laboratory abnormality that, in the
             opinion of the investigator, would interfere with the subject's ability to participate
             in the study. This includes an individual found to have an HIV dementia scale stage 3
             or 4.

          -  Any esophageal or other condition that would interfere with the swallowing of the
             study medication

          -  Use of excluded drugs as defined by the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ned Sacktor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infecious Diseas Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>January 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2011</results_first_posted>
  <last_update_submitted>January 28, 2011</last_update_submitted>
  <last_update_submitted_qc>January 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ned Sacktor, MD</name_title>
    <organization>Johns Hopkins School of Medicine</organization>
  </responsible_party>
  <keyword>Human immunodeficiency virus (HIV)</keyword>
  <keyword>HIV associated cognitive impairment</keyword>
  <keyword>HIV dementia</keyword>
  <keyword>Uganda</keyword>
  <keyword>Acquired immune deficiency syndrome (AIDS)</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from Mar 2008 to Oct 2009 when the study was stopped early (Data and Safety Monitoring Board (DSMB) decision based on futility) on Nov 2009. The study participants were recruited from the Infectious Disease Institute, Makerere University, Kampala, Uganda.</recruitment_details>
      <pre_assignment_details>Total of 353 participants were screened; only 73 were randomized and thus 280 were not enrolled: 146 of them did not have cognitive impairment, 55 of them lacked laboratory inclusion criteria, and 79 of them had &quot;others&quot;.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg orally every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo minocycline capsules every 12 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Step1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Study Closure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Step2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">26 participants completed STEP1; however, only 19 out of the 26 decided to enroll in STEP2.</participants>
                <participants group_id="P2" count="21">26 participants completed STEP1; however, only 21 out of the 26 decided to enroll in STEP2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Study Closure</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Initiation of antiretroviral therapy/ART</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg orally every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo minocycline capsules every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="8.21"/>
                    <measurement group_id="B2" value="36.7" spread="7.17"/>
                    <measurement group_id="B3" value="37.0" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Memorial Sloan Kettering (MSK) Acquired Immune Deficiency Syndrome (AIDS) Dementia Scale</title>
          <description>The Memorial Sloan Kettering (MSK) clinical scale was defined below:
Stage 0: normal
Stage 0.5: equivocal/subclinical
Stage 1: mild
Stage 2: moderate
Stage 3: severe
Stage 4: end stage</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Equivocal/subclinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cluster of Differentiation Four (CD4) Count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="319" lower_limit="251" upper_limit="469"/>
                    <measurement group_id="B2" value="305" lower_limit="252" upper_limit="500"/>
                    <measurement group_id="B3" value="313" lower_limit="251" upper_limit="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Log10(Human immunodeficiency virus (HIV) Ribonucleic Acid (RNA) Viral Load (VL))</title>
          <units>copies/mL</units>
          <param>Log Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.41" lower_limit="4.09" upper_limit="4.94"/>
                    <measurement group_id="B2" value="4.59" lower_limit="4.12" upper_limit="5.25"/>
                    <measurement group_id="B3" value="4.50" lower_limit="4.10" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Karnofsky's Performance Score</title>
          <description>100:Normal,90:normal;Minor Signs or Symptoms of Disease,80:Normal Activity with Effort;Some Signs or Symptoms of Disease,70:Cares for Self,Unable to Carry on Normal Activity or to Do Active Work,60:Requires Occasional Assistance but is Able to Care for Most of Needs,50:Requires Considerable Assistance and Frequent Medical Care,40:Disabled,Requires Special Care and Assistance,30:Severely Disabled; Hospitalization Indicated Although Death is Not Imminent,20:Very Sick; Hospitalization Necessary;Active Supportive Treatment is Necessary,10:Moribund, Fatal Processes Progressing Rapidly,0:Death</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>80 (Karnofsky Score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 (Karnofsky Score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 (Karnofsky Score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Instrumental Activities of Daily Living (IADL)</title>
          <description>16 tasks: Housekeeping,Managing Finances,Buying Groceries,Cooking,Planning Social Activities,Understanding Reading Materials/TV,Transportation,Using the Telephone,Home Repairs,Bathing,Dressing,Shopping,Laundry,Taking/Keeping Track of Medication,Child Care,Work.
For the baseline IADL measure, participants were given four choices to choose for having difficulty on the 16 tasks:Primarily Cognitive problems,Primarily physical problems,equally cognitive and physical problems,not having any difficulties on previous tasks.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primarily cognitive problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primarily physical problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not having any difficulties on the tasks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Overall Neurological Assessment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal neurological assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Nervous System (CNS) abnormality only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Nervous System (PNS) abnormality only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS and PNS abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Can not assess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Uganda Neuropsychological Test Battery Summary measure (U NP Sum)</title>
          <description>Uganda Neuropsychological Test Battery Summary measure (U NP Sum)is the average z-scores of the 9 neurupsychological tests:Grooved Pegboard Dominant Hand,Grooved Pegboard Non-dominant Hand,Color Trail1,Color Trail2,Symbol Digit,WHO/UCLA Verbal Learning Test Trial 5,WHO/UCLA Verbal Learning Test Delayed Recall,Digit Span-Forward,Digit Span-Backward Since the score depends on age and education levels, the raw score was standardized as follows: Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.97" spread="0.78" lower_limit="-1.16" upper_limit="-0.55"/>
                    <measurement group_id="B2" value="-0.97" spread="0.86" lower_limit="-1.18" upper_limit="-0.58"/>
                    <measurement group_id="B3" value="-0.97" spread="0.82" lower_limit="-1.18" upper_limit="-0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO-UCLA Auditory Verbal Learning Test (AVLT): Trials Total</title>
          <description>World Health Organization-University of California Los Angeles (WHO-UCLA) Auditory Verbal Learning Test (AVLT) is a full-scale memory assessment.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.28" spread="0.88"/>
                    <measurement group_id="B2" value="-1.48" spread="1.14"/>
                    <measurement group_id="B3" value="-1.38" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO-UCLA Auditory Verbal Learning Test (AVLT): Delayed</title>
          <description>World Health Organization-University of California Los Angeles (WHO-UCLA) Auditory Verbal Learning Test (AVLT) is a memory assessment.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.17" spread="0.79"/>
                    <measurement group_id="B2" value="-1.15" spread="1.18"/>
                    <measurement group_id="B3" value="-1.16" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Color Trails 1</title>
          <description>The Color Trails tests measure speed of attention, sequencing, mental flexibility, visual search, and motor function.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.35" spread="2.03"/>
                    <measurement group_id="B2" value="-1.65" spread="3.03"/>
                    <measurement group_id="B3" value="-1.51" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Color Trails 2</title>
          <description>The Color Trails tests measure speed of attention, sequencing, mental flexibility, visual search, and motor function.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.55" spread="2.07"/>
                    <measurement group_id="B2" value="-2.33" spread="2.05"/>
                    <measurement group_id="B3" value="-2.44" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Grooved Pegboard Dominant</title>
          <description>The grooved pegboard is a manipulative dexterity test requiring rapid visual-motor coordination. The test is completed using the dominant hand (GPD) and then using the non-dominant hand (GPN). The score for each hand is the time in seconds that the participant takes to complete the entire board.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.34" spread="1.58"/>
                    <measurement group_id="B2" value="-0.03" spread="1.14"/>
                    <measurement group_id="B3" value="-0.18" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Grooved Pegboard Non-dominant</title>
          <description>The grooved pegboard is a manipulative dexterity test requiring rapid visual-motor coordination. The test is completed using the dominant hand (GPD) and then using the non-dominant hand (GPN). The score for each hand is the time in seconds that the participant takes to complete the entire board.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.56" spread="1.82"/>
                    <measurement group_id="B2" value="-0.48" spread="1.42"/>
                    <measurement group_id="B3" value="-0.52" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symbol Digit</title>
          <description>This test assesses the participant's ability to maintain rapid visual-motor sequencing in a timed test. The score is the total number of correctly transcribed numbers in the time limit (90 seconds). Participants receive 1 point for each item filled in correctly. Maximum score is 110 points.
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.87" spread="0.96"/>
                    <measurement group_id="B2" value="-0.86" spread="0.80"/>
                    <measurement group_id="B3" value="-0.86" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digit Span Backward</title>
          <description>Digit span assesses attention, concentration, and mental control(e.g., Repeat the numbers 1-2-3 in reverse sequence).
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.68" spread="0.75"/>
                    <measurement group_id="B2" value="-0.94" spread="1.06"/>
                    <measurement group_id="B3" value="-0.81" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digit Span Forward</title>
          <description>Digit span assesses attention, concentration, and mental control(e.g., Repeat the numbers 1-2-3 in reverse sequence).
Since the score depends on age and education levels, the raw score was standardized as follows:
Zx =(x − μx)/σx where Zx is the age and education adjusted z-score, x is the raw score, and μx and σx are the age and education stratified norms.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.02" spread="0.79"/>
                    <measurement group_id="B2" value="0.19" spread="0.99"/>
                    <measurement group_id="B3" value="0.11" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)</title>
        <description>The U NP Sum is defined as the average of z scores for 9 neuropsychological test subcomponents in the neuropsychological test battery (i.e. the average of norm-adjusted (&quot;z&quot;) scores for Grooved Pegboard Dominant Hand, Grooved Pegboard Non-dominant Hand, Color Trails 1, Color Trails 2, Symbol Digit, WHO-UCLA Verbal Learning test Trial 5, WHO-UCLA Verbal Learning test delayed recall, Digit Span forward and Digit Span backward). The outcome is defined as U NP Sum at week 24 - U NP Sum at baseline.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>The descriptive statistics are based on per protocol analysis. For the statistical analysis, ITT analysis was used and the missing U NP Sums at week 24 were imputed using a multiple regression imputation method. The number of participants analyzed for the ITT analysis was 73 (36 for Minocycline and 37 for Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)</title>
          <description>The U NP Sum is defined as the average of z scores for 9 neuropsychological test subcomponents in the neuropsychological test battery (i.e. the average of norm-adjusted (&quot;z&quot;) scores for Grooved Pegboard Dominant Hand, Grooved Pegboard Non-dominant Hand, Color Trails 1, Color Trails 2, Symbol Digit, WHO-UCLA Verbal Learning test Trial 5, WHO-UCLA Verbal Learning test delayed recall, Digit Span forward and Digit Span backward). The outcome is defined as U NP Sum at week 24 - U NP Sum at baseline.</description>
          <population>The descriptive statistics are based on per protocol analysis. For the statistical analysis, ITT analysis was used and the missing U NP Sums at week 24 were imputed using a multiple regression imputation method. The number of participants analyzed for the ITT analysis was 73 (36 for Minocycline and 37 for Placebo).</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.74"/>
                    <measurement group_id="O2" value="0.49" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the 24-week changes of U NP Sum between the minocycline and placebo groups are the same.
The sample size calculation showed that 100 (50 participants in each group) were required to detect the clinically meaningful difference of 0.5 with 85% power, 0.05 Type I error, two-sample and two-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.512</ci_lower_limit>
            <ci_upper_limit>0.460</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage</title>
        <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>The descriptive statistics were based on observed data. Since all participants reported there were no change in the MSK score at week 24, no statistical test was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage</title>
          <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
          <population>The descriptive statistics were based on observed data. Since all participants reported there were no change in the MSK score at week 24, no statistical test was conducted.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change/Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of Karnofsky Performance Score</title>
        <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>This analysis includes the participants with Karnofsky performance score at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of Karnofsky Performance Score</title>
          <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
          <population>This analysis includes the participants with Karnofsky performance score at baseline and week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change/Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the percentage of participants feeling &quot;better&quot; in the minocycline group after 24 week treatment is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.613</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.</title>
        <description>The outcome is the time to first Grade ≥ 2 toxicity and/or sign and symptoms from study treatment initiation up to week 24. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
        <time_frame>Time of initial Grade ≥ 2 toxicity and/or sign and symptom event up to week 24</time_frame>
        <population>This analysis includes every randomized participants. A total of 21 minocycline and 20 placebo participants reported at least one Grade ≥ 2 toxicity and/or sign and symptoms during 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.</title>
          <description>The outcome is the time to first Grade ≥ 2 toxicity and/or sign and symptoms from study treatment initiation up to week 24. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
          <population>This analysis includes every randomized participants. A total of 21 minocycline and 20 placebo participants reported at least one Grade ≥ 2 toxicity and/or sign and symptoms during 24 weeks</population>
          <units>participants with an event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.01 - 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.01 - 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the survival curve for the first Grade ≥ 2 toxicity and/or sign and symptoms in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.661</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms</title>
        <description>The outcome is the time of first Grade ≥ 2 toxicity and/or sign and symptoms from treatment initiation up to 48 weeks. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
        <time_frame>Time of first Grade ≥ 2 toxicity and/or sign and symptom event up to 48 weeks</time_frame>
        <population>This analysis includes every randomized participants. A total of 22 minocycline and 21 placebo participants reported at least one Grade ≥ 2 toxicity and/or sign and symptoms during 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms</title>
          <description>The outcome is the time of first Grade ≥ 2 toxicity and/or sign and symptoms from treatment initiation up to 48 weeks. The grade was determined by clinicians and an Grade ≥ 2 event means moderate, severe, life-threatening, or death event.</description>
          <population>This analysis includes every randomized participants. A total of 22 minocycline and 21 placebo participants reported at least one Grade ≥ 2 toxicity and/or sign and symptoms during 48 weeks.</population>
          <units>participants with an event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.01-12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.01-24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24.01-48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the 48-week survival curve for the first Grade ≥ 2 toxicity and/or sign and symptoms in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.941</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of CD4 Cell Counts</title>
        <description>The outcome is defined as CD4 cell count at week 24 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>This analysis used the participants with CD4 cell counts at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of CD4 Cell Counts</title>
          <description>The outcome is defined as CD4 cell count at week 24 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
          <population>This analysis used the participants with CD4 cell counts at baseline and week 24.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.28" spread="70.85"/>
                    <measurement group_id="O2" value="-28.57" spread="61.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the mean 24-week change of CD4 cell counts in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The model was adjusted for the baseline CD4 counts.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.23</ci_lower_limit>
            <ci_upper_limit>43.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>48-week Change of CD4 Cell Counts</title>
        <description>The outcome is defined as CD4 cell count at week 48 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
        <time_frame>At baseline and week 48</time_frame>
        <population>This analysis used the participants with CD4 cell counts at baseline and week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>48-week Change of CD4 Cell Counts</title>
          <description>The outcome is defined as CD4 cell count at week 48 - CD4 cell count at baseline. The unit is cells/mm^3.</description>
          <population>This analysis used the participants with CD4 cell counts at baseline and week 48.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.15" spread="80.46"/>
                    <measurement group_id="O2" value="-56.50" spread="84.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the mean 48-week change in CD4 cell counts in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The model was adjusted for the baseline CD4 counts.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>32.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.07</ci_lower_limit>
            <ci_upper_limit>74.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of Instrumental Activities of Daily Living</title>
        <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>The analysis includes participants with IADL scores at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of Instrumental Activities of Daily Living</title>
          <description>The outcome is a new dichotomous variable: no change/worse vs. better at 24 weeks compared to baseline.</description>
          <population>The analysis includes participants with IADL scores at baseline and week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change/Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the percentage of being &quot;better&quot; at week 24 compared to baseline in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.764</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The model was not adjusted for any covariate (due to small number of being &quot;better&quot; in both groups.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>6.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)</title>
        <description>The outcome is the HIV RNA plasma viral loads (Log10 transformed) at week 24 - the viral loads (Log10 transformed) at baseline.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>The analysis includes participants with HIV RNA viral loads at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)</title>
          <description>The outcome is the HIV RNA plasma viral loads (Log10 transformed) at week 24 - the viral loads (Log10 transformed) at baseline.</description>
          <population>The analysis includes participants with HIV RNA viral loads at baseline and week 24.</population>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="-0.14" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.13" lower_limit="-0.23" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the median log10-transformed HIV RNA viral loads in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The chi-square score was 0.024 and the degree of freedom was 1.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score</title>
        <description>The outcome is the total CES-D score at week 24 - the total CES-D score at baseline.
The total CES-D score is based on 20 CES-D items, such as &quot;I was bothered by things that usually don't bother me&quot; and &quot;I did not feel like eating, my appetite was poor&quot;. Patients were asked to answer each item by 4 scales: (1) Rarely, (2) Sometimes, (3) Occasionally, and (4) Most of the time. After 4 negative items were multiplied by -1, the total CES-D score is a simple sum of all items.
The min and Max are 0 and 60, respectively. Higher scores indicate more severe depressive symptoms.</description>
        <time_frame>At baseline and week 24</time_frame>
        <population>The analysis includes participants with CES-D scores at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo minocycline capsules every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score</title>
          <description>The outcome is the total CES-D score at week 24 - the total CES-D score at baseline.
The total CES-D score is based on 20 CES-D items, such as &quot;I was bothered by things that usually don't bother me&quot; and &quot;I did not feel like eating, my appetite was poor&quot;. Patients were asked to answer each item by 4 scales: (1) Rarely, (2) Sometimes, (3) Occasionally, and (4) Most of the time. After 4 negative items were multiplied by -1, the total CES-D score is a simple sum of all items.
The min and Max are 0 and 60, respectively. Higher scores indicate more severe depressive symptoms.</description>
          <population>The analysis includes participants with CES-D scores at baseline and week 24.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.19" spread="10.86"/>
                    <measurement group_id="O2" value="-4.04" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the mean 24-week change of CES-D score in the minocycline group is the same as the one in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The model was adjusted for the baseline CES-D and MSK scores.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.40</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>The lab assessments were conducted at weeks 0, 12, 24, and 48.</desc>
      <group_list>
        <group group_id="E1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg orally every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo minocycline capsules every 12 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Appendix 76</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Sgpt</sub_title>
                <description>The lab value was 836 when the normal value was 45.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sgot</sub_title>
                <description>The lab value was 901 when the normal value was 40.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>The patient died due to Pulmonary Tuberculosis. The cause of death was unrelated to the study treatment as she was not on the study treatment at the time of her death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Potassium</sub_title>
                <description>The participant had high potassium level. The value was 7.8 when the normal limit was 5.3.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Appendix 76</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Absolute Neutrophil Count</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="36"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>White Blood Cells</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Carbon Dioxide</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SGOT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphorus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sodium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The estimated sample size was 100; however, due to early termination of the study, the total number of randomized participants was 73.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sachiko Miyahara</name_or_title>
      <organization>Harvard School of Public Health</organization>
      <phone>617-432-2837</phone>
      <email>miyahara@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

